-
公开(公告)号：US20110263681A1
公开(公告)日：2011-10-27
申请号：US13090580
申请日：2011-04-20
Applicant: Antonin DE FOUGEROLLES , John L. DIENER , Emma HICKMAN , Gregory HINKLE , Stuart MILSTEIN , Anne-Marie PULICHINO , Andrew SPRAGUE
Inventor： Antonin DE FOUGEROLLES , John L. DIENER , Emma HICKMAN , Gregory HINKLE , Stuart MILSTEIN , Anne-Marie PULICHINO , Andrew SPRAGUE
CPC classification number: C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
Abstract translation: 本公开涉及可用于使用治疗有效量治疗β-ENAC相关疾病如囊性纤维化，1型假性醛固酮增多症（1例（PHA1），跛行综合征，高血压，碱中毒，低钾血症和肥胖相关性高血压）的方法中的RNAi剂 的RNAi试剂到β-ENaC。
-
公开(公告)号：US09000143B2
公开(公告)日：2015-04-07
申请号：US12982261
申请日：2010-12-30
Applicant: Antonin de Fougerolles , Andrew Sprague , Jens Harborth , Maria Gabriela Belvisi , Mark Andrew Birrell , Elizabeth Louise Hardaker , Matthew Copeland Catley
Inventor： Antonin de Fougerolles , Andrew Sprague , Jens Harborth , Maria Gabriela Belvisi , Mark Andrew Birrell , Elizabeth Louise Hardaker , Matthew Copeland Catley
IPC: C07H21/04 , C12N15/113
CPC classification number: C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12Y207/1101 , C12N2310/3521
Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.
Abstract translation: 本发明涉及用于抑制IKK-B基因表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸，长度通常为19-25个核苷酸的核苷酸序列的反义链，以及 其基本上与IKK-B基因的至少一部分互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 使用该药物组合物治疗由IKK-B基因的表达或活化引起的疾病的方法; 以及抑制细胞中IKK-B基因表达的方法。
-
公开(公告)号：US20130012571A1
公开(公告)日：2013-01-10
申请号：US13614836
申请日：2012-09-13
Applicant: Antonin DE FOUGEROLLES , John L. DIENER , Emma HICKMAN , Gregory HINKLE , Stuart MILSTEIN , Anne-Marie PULICHINO , Andrew SPRAGUE
Inventor： Antonin DE FOUGEROLLES , John L. DIENER , Emma HICKMAN , Gregory HINKLE , Stuart MILSTEIN , Anne-Marie PULICHINO , Andrew SPRAGUE
CPC classification number: C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
Abstract translation: 本公开涉及可用于使用治疗有效量治疗β-ENAC相关疾病如囊性纤维化，1型假性醛固酮增多症（1例（PHA1），跛行综合征，高血压，碱中毒，低钾血症和肥胖相关性高血压）的方法中的RNAi剂 的RNAi试剂到β-ENaC。
-
公开(公告)号：US20110112178A1
公开(公告)日：2011-05-12
申请号：US12982261
申请日：2010-12-30
Applicant: Antonin de Fougerolles , Andrew Sprague , Jens Harborth , Maria Gabriela Belvisi , Mark Andrew Birrell , Elizabeth Ouise Hardaker , Matthew Copeland Catley
Inventor： Antonin de Fougerolles , Andrew Sprague , Jens Harborth , Maria Gabriela Belvisi , Mark Andrew Birrell , Elizabeth Ouise Hardaker , Matthew Copeland Catley
IPC: A61K31/713 , C07H21/02 , C12N15/63 , C12N5/00 , A61P29/00
CPC classification number: C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12Y207/1101 , C12N2310/3521
Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.
Abstract translation: 本发明涉及用于抑制IKK-B基因表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸，长度通常为19-25个核苷酸的核苷酸序列的反义链，以及 其基本上与IKK-B基因的至少一部分互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 使用该药物组合物治疗由IKK-B基因的表达或活化引起的疾病的方法; 以及抑制细胞中IKK-B基因表达的方法。
-
公开(公告)号：US20120122960A1
公开(公告)日：2012-05-17
申请号：US13355879
申请日：2012-01-23
Applicant: Antonin DE FOUGEROLLES , John L. DIENER , Emma HICKMAN , Gregory HINKLE , Stuart MILSTEIN , Anne-Marie PULICHINO , Andrew SPRAGUE
Inventor： Antonin DE FOUGEROLLES , John L. DIENER , Emma HICKMAN , Gregory HINKLE , Stuart MILSTEIN , Anne-Marie PULICHINO , Andrew SPRAGUE
CPC classification number: C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
-
Patent Agency Ranking
公开(公告)号：US08344127B2
公开(公告)日：2013-01-01
申请号：US13090580
申请日：2011-04-20
Applicant: Antonin De Fougerolles , John L. Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Sprague
Inventor： Antonin De Fougerolles , John L. Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Sprague
CPC classification number: C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
Abstract translation: 本公开涉及可用于使用治疗有效量治疗β-ENAC相关疾病如囊性纤维化，1型假性醛固酮增多症（1例（PHA1），跛行综合征，高血压，碱中毒，低钾血症和肥胖相关性高血压）的方法中的RNAi剂 的RNAi试剂到β-ENaC。
-
公开(公告)号：US07888498B2
公开(公告)日：2011-02-15
申请号：US11751283
申请日：2007-05-21
Applicant: Antonin De Fougerolles , Andrew Sprague , Jens Harborth , Maria Gabriela Belvisi , Mark Andrew Birrell , Elizabeth Louise Hardaker , Matthew Copeland Catley
Inventor： Antonin De Fougerolles , Andrew Sprague , Jens Harborth , Maria Gabriela Belvisi , Mark Andrew Birrell , Elizabeth Louise Hardaker , Matthew Copeland Catley
CPC classification number: C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12Y207/1101 , C12N2310/3521
Abstract: The invention relates to a doable-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases, caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.
Abstract translation: 本发明涉及用于抑制IKK-B基因表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸，长度通常为19-25个核苷酸的核苷酸序列的反义链，以及 其基本上与IKK-B基因的至少一部分互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于使用该药物组合物治疗由IKK-B基因的表达或活化引起的疾病的方法; 以及抑制细胞中IKK-B基因表达的方法。
-
公开(公告)号：US20120115934A1
公开(公告)日：2012-05-10
申请号：US13355930
申请日：2012-01-23
Applicant: Antonin DE FOUGEROLLES , John L. DIENER , Emma HICKMAN , Gregory HINKLE , Stuart MILSTEIN , Anne-Marie PULICHINO , Andrew SPRAGUE
Inventor： Antonin DE FOUGEROLLES , John L. DIENER , Emma HICKMAN , Gregory HINKLE , Stuart MILSTEIN , Anne-Marie PULICHINO , Andrew SPRAGUE
CPC classification number: C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
Abstract translation: 本公开涉及可用于使用治疗有效量治疗β-ENAC相关疾病如囊性纤维化，1型假性醛固酮增多症（1例（PHA1），跛行综合征，高血压，碱中毒，低钾血症和肥胖相关性高血压）的方法中的RNAi剂 的RNAi试剂到β-ENaC。
-
公开(公告)号：US20120115933A1
公开(公告)日：2012-05-10
申请号：US13355903
申请日：2012-01-23
Applicant: Antonin DE FOUGEROLLES , John L. DIENER , Emma HICKMAN , Gregory HINKLE , Stuart MILSTEIN , Anne-Marie PULICHINO , Andrew SPRAGUE
Inventor： Antonin DE FOUGEROLLES , John L. DIENER , Emma HICKMAN , Gregory HINKLE , Stuart MILSTEIN , Anne-Marie PULICHINO , Andrew SPRAGUE
CPC classification number: C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
-
公开(公告)号：US20080108584A1
公开(公告)日：2008-05-08
申请号：US11751283
申请日：2007-05-21
Applicant: ANTONIN DE FOUGEROLLES , ANDREW SPRAGUE , JENS HARBORTH , MARIA BELVISI , MARK BIRRELL , ELIZABETH HARDAKER , MATTHEW CATLEY
Inventor： ANTONIN DE FOUGEROLLES , ANDREW SPRAGUE , JENS HARBORTH , MARIA BELVISI , MARK BIRRELL , ELIZABETH HARDAKER , MATTHEW CATLEY
IPC: A61K31/7052 , A61P29/00 , C07H21/02 , C12N15/63 , C12N5/00
CPC classification number: C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12Y207/1101 , C12N2310/3521
Abstract: The invention relates to a doable-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases, caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.
Abstract translation: 本发明涉及用于抑制IKK-B基因表达的双链核糖核酸（dsRNA），其包含长度小于30个核苷酸，长度通常为19-25个核苷酸的核苷酸序列的反义链，以及 其基本上与IKK-B基因的至少一部分互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 使用该药物组合物治疗由IKK-B基因的表达或活化引起的疾病的方法; 以及抑制细胞中IKK-B基因表达的方法。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.022 seconds)
